SLEB1
MCID: SYS043
MIFTS: 44

Systemic Lupus Erythematosus 1 (SLEB1)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Systemic Lupus Erythematosus 1

MalaCards integrated aliases for Systemic Lupus Erythematosus 1:

Name: Systemic Lupus Erythematosus 1 57 73
Systemic Lupus Erythematosus, Susceptibility to, 1 57 28
Systemic Lupus Erythematosus, Resistance to 57 12
Sleb1 57 73
Lupus Erythematosus, Systemic, Type 1 38
Lupus Erythematosus, Systemic 71
Systemic Lupus Erythematosus 57

Classifications:



External Ids:

OMIM® 57 601744
MeSH 43 D008180
UMLS 71 C0024141

Summaries for Systemic Lupus Erythematosus 1

UniProtKB/Swiss-Prot: 73 A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary: Systemic Lupus Erythematosus 1, also known as systemic lupus erythematosus, susceptibility to, 1, is related to systemic lupus erythematosus 16 and systemic lupus erythematosus 17, and has symptoms including pruritus and seizures. An important gene associated with Systemic Lupus Erythematosus 1 is TLR5 (Toll Like Receptor 5). The drugs Trimethoprim and Sulfamethoxazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone.

More information from OMIM: 601744

Related Diseases for Systemic Lupus Erythematosus 1

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 17 Systemic Lupus Erythematosus 1
Systemic Lupus Erythematosus 2 Systemic Lupus Erythematosus 3
Systemic Lupus Erythematosus 4 Systemic Lupus Erythematosus 5
Systemic Lupus Erythematosus 6 Systemic Lupus Erythematosus 7
Systemic Lupus Erythematosus 8 Systemic Lupus Erythematosus 9
Systemic Lupus Erythematosus 10 Systemic Lupus Erythematosus 11
Systemic Lupus Erythematosus 12 Systemic Lupus Erythematosus 13
Systemic Lupus Erythematosus 14 Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2321)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 12.0
2 systemic lupus erythematosus 17 11.8
3 neonatal systemic lupus erythematosus 11.8
4 vitiligo-associated multiple autoimmune disease susceptibility 1 11.7
5 pediatric systemic lupus erythematosus 11.7
6 systemic lupus erythematosus 2 11.7
7 systemic lupus erythematosus 10 11.7
8 libman-sacks endocarditis 11.7
9 systemic lupus erythematosus 9 11.7
10 systemic lupus erythematosus 6 11.7
11 systemic lupus erythematosus 11 11.7
12 drug-induced lupus erythematosus 11.7
13 mixed connective tissue disease 11.7
14 systemic lupus erythematosus with hemolytic anemia 1 11.7
15 sjogren syndrome 11.7
16 autoimmune disease 11.6
17 c1q deficiency 11.6
18 systemic lupus erythematosus 3 11.6
19 systemic lupus erythematosus 4 11.6
20 systemic lupus erythematosus 7 11.6
21 systemic lupus erythematosus 8 11.6
22 systemic lupus erythematosus 15 11.6
23 systemic lupus erythematosus 13 11.6
24 systemic lupus erythematosus 5 11.6
25 systemic lupus erythematosus 12 11.6
26 systemic lupus erythematosus 14 11.6
27 systemic lupus erythematosus with nephritis 1 11.6
28 systemic lupus erythematosus with nephritis 2 11.6
29 systemic lupus erythematosus with nephritis 3 11.6
30 systemic scleroderma 11.5
31 cutaneous lupus erythematosus 11.5
32 raynaud disease 11.5
33 spondyloenchondrodysplasia with immune dysregulation 11.5
34 complement component 2 deficiency 11.5
35 anemia, autoimmune hemolytic 11.4
36 antiphospholipid syndrome 11.4
37 aicardi-goutieres syndrome 11.4
38 chilblain lupus 1 11.4
39 neonatal lupus erythematosus 11.4
40 lupus erythematosus tumidus 11.4
41 discoid lupus erythematosus 11.4
42 fibromyalgia 11.4
43 complement factor i deficiency 11.4
44 hemophagocytic lymphohistiocytosis, familial, 1 11.4
45 macrophage activation syndrome 11.4
46 autoinflammatory syndrome, familial, with or without immunodeficiency 11.4
47 collagen disease 11.4
48 vasculitis 11.4
49 exanthem 11.4
50 neuromyelitis optica 11.4

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus 1:



Diseases related to Systemic Lupus Erythematosus 1

Symptoms & Phenotypes for Systemic Lupus Erythematosus 1

Clinical features from OMIM®:

601744 (Updated 08-Dec-2022)

UMLS symptoms related to Systemic Lupus Erythematosus 1:


pruritus; seizures

Drugs & Therapeutics for Systemic Lupus Erythematosus 1

Drugs for Systemic Lupus Erythematosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
2
Sulfamethoxazole Approved Phase 4 723-46-6 5329
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
5
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
6
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
8
Simvastatin Approved Phase 4 79902-63-9 54454
9
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
10 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
11 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
12
Rosuvastatin Calcium Phase 4 147098-20-2
13 Angiogenesis Inhibitors Phase 4
14 Hypoglycemic Agents Phase 4
15 Omega 3 Fatty Acid Phase 4
16 Hydroxycholecalciferols Phase 4
17 Complement System Proteins Phase 4
18 Complement C3 Phase 4
19 Hypolipidemic Agents Phase 4
20 Anticholesteremic Agents Phase 4
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
22 Lipid Regulating Agents Phase 4
23
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
24
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
25
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
26
Belimumab Approved Phase 3 356547-88-1
27
Ramipril Approved Phase 2, Phase 3 87333-19-5 5362129
28
Aldesleukin Approved Phase 3 110942-02-4
29
Warfarin Approved Phase 2, Phase 3 81-81-2, 129-06-6 54678486
30
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8 9875401
31
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
32
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643
33
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
34
Rituximab Approved Phase 3 174722-31-7
35
Abatacept Approved Phase 2, Phase 3 332348-12-6
36
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
37
Acetaminophen Approved Phase 3 103-90-2 1983
38
Histamine Approved, Investigational Phase 3 51-45-6 774
39
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
40
Promethazine Approved, Investigational Phase 3 60-87-7 4927
41
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
42
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
43
Hydroxychloroquine Approved Phase 3 118-42-3 3652
44
Infliximab Approved Phase 2, Phase 3 170277-31-3
45
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181
46
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
47
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 6279 10631
48
Prasterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8 5280382 445354
50
Abetimus Investigational Phase 3 167362-48-3

Interventional clinical trials:

(show top 50) (show all 773)
# Name Status NCT ID Phase Drugs
1 Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial Unknown status NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
4 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
5 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
6 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Completed NCT02953821 Phase 4 Acthar Gel;Placebo Gel
7 A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus Completed NCT03098823 Phase 4 RAYOS;Prednisone
8 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
9 A Single Arm, 24 Weeks, Pilot Study of Belimumab In Treatment of Early Systemic Lupus Erythematosus Completed NCT04956484 Phase 4 Standard of care
10 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
11 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Completed NCT01705977 Phase 4
12 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin
13 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
14 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
15 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
16 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
17 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
18 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
19 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
20 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
21 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Completed NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;standard dose of HCQ
22 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
23 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
24 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
25 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
26 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
27 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Completed NCT01753401 Phase 4 Acthar;Placebo;Steroid Drug
28 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
29 Pilot Trial of Belimumab in Early Lupus Recruiting NCT03543839 Phase 4
30 A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus Recruiting NCT04127747 Phase 4 Standard dose of rituximab;Individualized dose of rituximab
31 Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study Recruiting NCT04447053 Phase 4 Belimumab Injection [Benlysta]
32 A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT04908865 Phase 4 Belimumab;Standard therapy
33 Efficacy and Safety of Belimumab for Prevention of Disease Flares in SLE Patients With Low Disease Activity Recruiting NCT04515719 Phase 4
34 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Crossover Study Evaluating the Safety and Immunogenicity of the Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus Not yet recruiting NCT05559671 Phase 4
35 A Model to Early Predict the Response of Belimumab Treatment in the Patients With Systemic Lupus Erythematosus Not yet recruiting NCT04893161 Phase 4 Belimumab
36 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
37 Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus Withdrawn NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
38 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
39 The Effect of Milnacipran on Fatigue and Quality of Life in a Lupus Cohort Withdrawn NCT01359826 Phase 4 Milnacipran
40 Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease Withdrawn NCT01276782 Phase 4 Levothyroxine
41 The Safety and Efficacy of the Traditional Chinese Medicine Zishenqing in Subjects With Active Systemic Lupus Erythematosus Unknown status NCT04275193 Phase 2, Phase 3 Zishenqing;Placebo
42 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
43 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment (Prednisone 5 Milligram Per Day) in Quiescent Systemic Lupus Unknown status NCT02558517 Phase 3 prednisone discontinuation
44 A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)
45 Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial Unknown status NCT03178188 Phase 2, Phase 3
46 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
47 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
48 Randomized Trial of High-Dose IV Cyclophosphamide Versus Monthly IV Cyclophosphamide Completed NCT00005778 Phase 3 High-dose immunoablative therapy
49 An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Completed NCT03427151 Phase 3 IPP-201101
50 A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE) Completed NCT00624338 Phase 2, Phase 3 Atacicept 75 mg;Atacicept 150 mg

Search NIH Clinical Center for Systemic Lupus Erythematosus 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclosporine
Hydroxychloroquine
Hydroxychloroquine Sulfate
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide

Genetic Tests for Systemic Lupus Erythematosus 1

Genetic tests related to Systemic Lupus Erythematosus 1:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus, Susceptibility to, 1 28 TLR5

Anatomical Context for Systemic Lupus Erythematosus 1

Organs/tissues related to Systemic Lupus Erythematosus 1:

MalaCards : Bone Marrow, T Cells, Bone, Skin, Endothelial, B Cells, Myeloid

Publications for Systemic Lupus Erythematosus 1

Articles related to Systemic Lupus Erythematosus 1:

(show top 50) (show all 30056)
# Title Authors PMID Year
1
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. 62 57
16027372 2005
2
The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. 62 57
11172029 2001
3
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. 62 57
9843982 1998
4
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. 62 57
9045876 1997
5
Regulation of B cell tolerance by the lupus susceptibility gene Ly108. 57
16778059 2006
6
Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. 57
9502778 1998
7
Susceptibility loci for lupus: a guiding light from murine models? 57
9045853 1997
8
Nitrogen dioxide and hospital length of stay and cost for systemic lupus erythematosus in Hunan, China. 62
36162573 2023
9
Systemic lupus erythematosus and cardiovascular disease. 62
35982610 2023
10
Effectiveness of custom-made functional foot orthoses versus flat cushioning insoles on pain in patients with systemic lupus erythematosus. 62
35786028 2023
11
Coexistence of sickle cell disease and systemic lupus erythematosus is associated with quantitative and qualitative impairments in circulating regulatory B cells. 62
36184367 2022
12
Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. 62
36006459 2022
13
Addressing health disparities as a function of ethnicity in systemic lupus erythematosus patients. 62
36036891 2022
14
Increased HIF-1α expression in T cells and associated with enhanced Th17 pathway in systemic lupus erythematosus. 62
35599104 2022
15
The association between hydroxychloroquine use and future development of systemic lupus erythematosus in patients with primary Sjögren's syndrome. 62
36089698 2022
16
Montreal cognitive assessment as a screening instrument for cognitive impairment in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. 62
36218127 2022
17
Peripheral immunophenotypes associated with the flare in the systemic lupus erythematosus patients with low disease activity state. 62
36270468 2022
18
Pregnancy and lactation-associated osteoporosis in a Systemic Lupus Erythematosus patient. 62
36274494 2022
19
Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population. 62
36206015 2022
20
Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence. 62
36243406 2022
21
A functional microRNA binding site variant in IL-23R gene in systemic lupus erythematosus and rheumatoid arthritis: is there any correlation? 62
36214949 2022
22
Expression of the miR-9-5p, miR-125b-5p and its target gene NFKB1 and TRAF6 in childhood-onset systemic lupus erythematosus (cSLE). 62
36177494 2022
23
Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis. 62
36148853 2022
24
Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. 62
36325952 2022
25
Association between AhR in B cells and systemic lupus erythematosus with renal damage. 62
36327874 2022
26
Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies. 62
36169280 2022
27
Association between the interferon-γ +874 T/A polymorphism and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis. 62
36031708 2022
28
Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus. 62
36453450 2022
29
A Boy Presenting with a Fever and Pancytopenia Diagnosed with Systemic Lupus Erythematosus without a Positive Anti-ds-DNA Antibody Result or Hypocomplementemia: A Case Report. 62
36420549 2022
30
Vitamin D Presented In Vitro Immunomodulatory Property on T Lymphocyte-Related Cytokines in Systemic Lupus Erythematosus. 62
36459355 2022
31
LncRNA IL21-AS1 interacts with hnRNPU protein to promote IL21 overexpression and aberrant differentiation of Tfh cells in systemic lupus erythematosus. 62
36447054 2022
32
Burden of Comorbidities Predicts 30-Day Rehospitalizations in Young Adult Medicare Beneficiaries With Systemic Lupus Erythematosus. 62
36455951 2022
33
mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus. 62
36265758 2022
34
New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: A case report and review of literature. 62
36246778 2022
35
Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome. 62
36463907 2022
36
High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: A possible relation to lupus nephritis. 62
36214106 2022
37
Science and visual Arts: Binomial or Dichotomy? A Pilot study in Systemic Lupus Erythematosus patients. 62
36189670 2022
38
Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. 62
36472065 2022
39
Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus. 62
36471199 2022
40
Altered degree centrality in patients with non-neuropsychiatric systemic lupus erythematosus: a resting-state fMRI study. 62
35046118 2022
41
Mitochondria as a key player in systemic lupus erythematosus. 62
35978536 2022
42
A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus. 62
35064901 2022
43
Effectiveness of anti-interleukin-17-receptor antibody for hydroxychloroquine-induced generalized pustular psoriasis in a patient with systemic lupus erythematosus. 62
35838273 2022
44
Acquired FXI deficiency in a systemic lupus erythematosus patient: Evolution and coagulation phenotypic changed to lupus anticoagulant during immunosuppressive therapy. 62
35883223 2022
45
HERC6 is upregulated in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and promotes the disease progression. 62
35880641 2022
46
COVID-19 infection triggered juvenile systemic lupus erythematosus-like disease. 62
35838138 2022
47
Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus. 62
35939162 2022
48
Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. 62
35977808 2022
49
Proteomics analysis of lysine crotonylation and 2-hydroxyisobutyrylation reveals significant features of systemic lupus erythematosus. 62
35941338 2022
50
A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA. 62
36471198 2022

Variations for Systemic Lupus Erythematosus 1

Expression for Systemic Lupus Erythematosus 1

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 1.

Pathways for Systemic Lupus Erythematosus 1

GO Terms for Systemic Lupus Erythematosus 1

Sources for Systemic Lupus Erythematosus 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....